Related Experiment Video

Updated: Nov 18, 2025

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
04:01

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

1.5K

Ferroptosis as a novel therapeutic target for cardiovascular disease

Xiaoguang Wu1, Yi Li1, Shuchen Zhang1

  • 1Department of Cardiology, The Second Affiliated Hospital of Soochow University, Suzhou, China.

Theranostics
|February 4, 2021
PubMed

Insights

Ferroptosis, a cell death form driven by iron overload, impacts cardiovascular diseases. Targeting ferroptosis offers a new therapeutic strategy for heart conditions like cardiomyopathy and heart failure.

Area of Science:

  • Cardiovascular Medicine
  • Cell Death Research
  • Biochemistry

Background:

  • Cell death is central to cardiovascular disease pathophysiology.
  • Limited regeneration capacity in the heart necessitates understanding cell death mechanisms.
  • Ferroptosis, a regulated cell death, involves iron overload and lipid hydroperoxide accumulation.

Purpose of the Study:

  • To review ferroptosis mechanisms in cardiovascular disease.
  • To explore ferroptosis as a therapeutic target for heart conditions.

Main Methods:

  • Review of existing literature on ferroptosis.
  • Analysis of iron, lipid, amino acid, and glutathione metabolism in ferroptosis.
  • Examination of ferroptosis's role in cardiomyopathy, myocardial infarction, ischemia/reperfusion injury, and heart failure.

Main Results:

  • Ferroptosis is tightly regulated by iron, lipid, amino acid, and glutathione metabolism.
  • Ferroptosis is implicated in the progression of various cardiovascular diseases.
  • Understanding ferroptosis provides insights into cardiomyocyte death.

Conclusions:

  • Ferroptosis is a critical process in cardiovascular pathophysiology.
  • Targeting ferroptosis presents a novel therapeutic avenue for cardiovascular diseases.

Keywords:
cardiomyopathyferroptosisheart failureischemia/reperfusion injurymyocardial infarction

More Related Videos

Ferritinophagy: Assessing the Selective Degradation of Iron by Autophagy in Human Fibroblasts09:21

Ferritinophagy: Assessing the Selective Degradation of Iron by Autophagy in Human Fibroblasts

Published on: February 23, 2024

1.2K
Ferric Chloride-induced Murine Thrombosis Models10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

22.5K

Related Concept Videos

Necrosis01:16

Necrosis

Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
5.4K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
283
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
313
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
113
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
185
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
323